

Dr. Karamouzis is currently Assistant Professor in the Department of Biological Chemistry in Medical School, University of Athens, Greece. When Prof. Michalis Karamouzis was set in charge of the molecular oncology unit it had only the most basic infrastructure (tables, chairs and the chemical hood). Despite the initial difficult conditions in infrastructure, know-how and funding, Prof. Michalis Karamouzis succeeded in equipping the laboratory with basic instruments (western blot apparatus, water bath, pHmeter, pipettes etc.), chemicals and reagents. He started cell tissue cultures with human breast cancer cell lines, establishing a strong research program and creating a highly skilled and competent research group. He also formed collaborations with well-established cancer research scientists. Prof. Michalis Karamouzis' lab advanced in the proximity ligation assay technique that can evaluate dimerization of two proteins as well as enhance the signal of low abundant proteins *in situ*. At the moment the lab occupies one Post Doc as lab manager and researcher.

Prof. Michalis Karamouzis' national and international recognition counts 25 communications in International conferences and 35 in National conferences. He has participated in 10 round tables and was invited and gave 15 lectures in National conferences. He has 85 publications in international peer-reviewed journals listed in SCI which carry a sum of 534.265 impact factor and a mean impact factor of 6.285. His publications have achieved until now more than 600 citations. The average citation per year is 64 and the H-index is 14.

Prof Karamouzis has also served as a reviewer for many peer-reviewed international journals (such as Journal of Clinical Oncology, Breast Cancer Research, Cancer Letters, Journal of Cellular and Molecular Medicine, European Journal of Surgical Oncology, European Journal of Cancer). He has also served as an evaluator of scientific project proposals, both national and international.

In the context of the educational proceedings, Prof. Michael Karamouzis teaches in two undergraduate courses in Athens Medical School and Dental School on Biological Chemistry. His main teaching course is carcinogenesis and the impact of various signal transduction pathways in the initiation and progression of malignant tumors.

## **Education – Training**

### *Undergraduate studies*

1990 – 1995: Bachelor of Medicine and Bachelor of Surgery School of Medicine  
University of Patras, Patras, Greece

1995: General medical license awarded by Prefecture of Patras, Greece

### *Postgraduate studies*

Jan 1995 – Jan 1996: Master of Science in Pharmacokinetics and Toxicology in  
School of Medicine, University of Patras, Patras, Greece

Jan 1996 – Jan 1998: PhD in School of Medicine, University of Patras, Patras, Greece  
– Thesis: “Cross-talk of retinoid receptors and the transcription factor AP-1 in  
laryngeal carcinogenesis and possible applications in chemoprevention”

## **Previous working positions**

Sep 1998 – Jul 1999: Fellow of Internal Medicine, Department of Internal Medicine,  
251 Hospital of Greek Air Force, Athens, Greece

Jul 1999 – Mar 2001: Fellow of Internal Medicine, Department of Internal Medicine,  
University Hospital of Patras, Patras, Greece

Jun 2001– Jan 2002: Fellow of Hematology-Oncology, Division of Hematology-  
Oncology, Department of Medicine, University Hospital of Patras, Patras, Greece

Mar 2003– Mar 2006: Fellow of Medical Oncology, St. Savvas Anticancer-  
Oncological Hospital, Athens, Greece

Sep 2006 – Aug 2007: Visiting Assistant Professor, Division of Hematology-  
Oncology, Department of Medicine, University of Pittsburgh, USA

## **Awards**

- 1) State scholarships foundation for the 1<sup>st</sup>, 2<sup>nd</sup> and 3<sup>rd</sup> year of Prof. Karamouzis’  
studies in the School of Medicine, University of Patras
- 2) Honorable award from School of Medicine, University of Patras for his graduation  
rank (4<sup>th</sup> between 133 graduates with a grade 7.66)

- 3) 2<sup>nd</sup> prize for conference presentation during the 3<sup>rd</sup> International Conference on Breast Imaging, Venice, Italy, April 3-6, 2001
- 4) Prize for research presented at the 5th International HSBCR Congress, Athens, Greece, November 1-2, 2001
- 5) State scholarships foundation for graduation first at Master of Science in School of Medicine, University of Patras
- 6) 1<sup>st</sup> prize poster presentation at 8<sup>th</sup> Pan-Hellenic Mastology Congress, Thessaloniki, Greece, March 7-10, 2002
- 7) National Kapodistrian University of Athens Prize 2002 – « Fotinio's Examination for fighting cancer» for the paper «M.V. Karamouzis, E. Likaki-Karatza, F.A. Mpadra, P. Ravazoula, D. Koukouras, E. Tzorakoelephtherakis, A.G. Papavassiliou & H.P. Kalofonos: «Non-palpable breast carcinomas: correlation of mammographically detected malignant-appearing microcalcifications and molecular prognostic factors»
- 8) 1<sup>st</sup> prize congress presentation at 12<sup>th</sup> Pan-Hellenic Oncology Congress, Athens, Greece, November 27-30, 2003
- 9) Clinical Oncology Scholarship - Hellenic Society of Medical Oncology, 2005-2006
- 10) European Society of Medical Oncology (ESMO) Translational Fellowship Award 2010-2012

### **Participation in scientific societies**

- 1) Full ESMO Member (European Society of Medical Oncology) – *Chair of ESMO-Young Oncologists Committee (2010-2012)*
- 2) Active ASCO Member (American Society of Clinical Oncology)
- 3) Associate AACR Member (American Association of Cancer Research)

### **Founding of scientific societies**

- 1) Founding member and first Chairman of Patras Branch of the Scientific Association of Greek Medical Students and vice Chairman of the Scientific Association of Greek Medical Students (2005)

- 2) Founding member and Chairman of Patras Branch of the European Medical Students' Association (EMSA) (2005)

### **List of most significant publications**

- 1) M.V. Karamouzis, VG Gorgoulis, A.G. Papavassiliou: "Transcription factors and neoplasia: vistas in novel drug design", Clin Cancer Res, 8(6): 949-961, 2002. / Impact Factor: 7.338
- 2) A. Alexopoulos, D. Tryfonopoulos, M.V. Karamouzis, G. Gerasimidis, I. Karydas, K. Kandilis, J. Stavrakakis, H. Stavrinides, C. Georganta, A. Ardavanis & G. Rigatos: "Evidence for In Vivo Synergism between Docetaxel and Gemcitabine in Patients with Metastatic Breast Cancer". Ann Oncol, 15: 88-94, 2004. / Impact Factor: 6.452
- 3) A. Alexopoulos, M.V. Karamouzis, H. Stavrinides, A. Ardavanis, K. Kandilis, J. Stavrakakis, C. Georganta & G. Rigatos: "Phase II study of pegylated liposomal doxorubicin / Impact Factor: Caelyx<sup>®</sup>) and docetaxel as first line treatment in metastatic breast cancer" Ann Oncol, 15: 891-895, 2004. / Impact Factor: 6.452
- 4) M.V. Karamouzis & A.G. Papavassiliou: "Retinoid receptors cross talk in respiratory epithelium cancer chemoprevention", Trends in Molecular Medicine, 11: 10-16, 2005. / Impact Factor: 10.308
- 5) A.G. Papatsoris, M.V. Karamouzis & A.G. Papavassiliou: "Novel insights into the implication of the IGF-1 network in prostate cancer", Trends in Molecular Medicine, 11: 52-55, 2005. / Impact Factor: 10.308
- 6) M.V. Karamouzis & A.G. Papavassiliou: "The IGF-1 network in lung carcinoma therapeutics", Trends Mol Med, 12:595-602, 2006. / Impact Factor: 10.308
- 7) E.G. Iliopoulou, M.V. Karamouzis, I. Missitzis, A. Ardavanis, C.N. Baxebanis, G. Rigatos, M. Papamichail, S.A. Perez: "Increased frequency of CD4+ cells expressing CD161 in cancer patients", Clin Cancer Res, 12: 6901-6909, 2006. / Impact Factor: 7.388
- 8) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: "Roles of CREB-Binding Protein / Impact Factor: CBP/p300 in respiratory epithelium tumourigenesis", Cell Res, 17: 324-332, 2007. / Impact Factor: 9.417

- 9) M.V. Karamouzis, F.A. Badra & A.G. Papavassiliou: “Breast cancer: the upgraded role of HER-3 and HER-4”, Int J Biochem Cell Biol, 39: 851-856, 2007. / Impact Factor: 9.417
- 10) M.V. Karamouzis, S.A. Perez, D.V. Skarlos, A. Ardavanis, N.N. Sotiriadou, E.G. Iliopoulou, M.L. Salagianni, P.A. Sotiropoulou, G. Orfanos, C.N. Baxevanis, G. Rigatos & M Papamichail: “CD4+CD25+ Regulatory T Cell frequency in HER/neu positive and negative advanced stage breast cancer patients”, Clin Cancer Res, 13: 2714-2721, 2007. / Impact Factor: 7.338
- 11) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Intriguing issues of EGFR targeting in head and neck cancer”, Ann Oncol, 18: 962, 2007. / Impact Factor: 6.452
- 12) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Epigenetics in respiratory epithelium carcinogenesis: prevention and therapeutic challenges”, Cancer Treat Rev, 33: 284-288, 2007. / Impact Factor: 6.811
- 13) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Compartmentalization of EGFR signalling might potentiate the optimal use of EGFR inhibitors in cancer therapeutics”, Br J Cancer, 96: 1924-1925, 2007. / Impact Factor: 4.831
- 14) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: “Targeting post-translational modifications and functional regulation of the Ras superfamily of small G-proteins for anticancer drug development”, Nat Rev Drugs Discov, 6:541-555, 2007. / Impact Factor: 28.712
- 15) M.V. Karamouzis, J.R. Grandis & A. Argiris: “Therapies against epidermal growth factor receptor in aerodigestive carcinomas”. JAMA, 298: 70-82, 2007. / Impact Factor: 30.011
- 16) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “Trastuzumab – Mechanism of action and use in clinical practice”, New Engl J Med, 357: 1664, 2007. / Impact Factor: 53.484
- 17) M.V. Karamouzis & A. Argiris: “Update on the role of EGFR inhibitors in cancer therapeutics”, Cancer Treat Res, 135: 257-275, 2007. / Impact Factor: 6.811
- 18) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: “Thiazolidinediones and cardiovascular events: Is concomitant aspirin use a confounder?”, JAMA, 299: 1539, 2008. / Impact Factor: 30.011

- 19) M.V. Karamouzis, P.A. Konstantinopoulos & A.G. Papavassiliou: “ErbB/HER receptor family in breast cancer – The more we search the more we learn”, *Ann Oncol*, 19: 1020-1021, 2008. / Impact Factor: 6.452
- 20) M.V. Karamouzis, A. Argiris, D. Raben & R. Ferris: “Head and Neck Cancer”, *Lancet*, 371: 1695-1709, 2008. / Impact Factor: 33.633
- 21) P.A. Konstantinopoulos, M.V. Karamouzis & A.G. Papavassiliou: “Educational and Social-Ethical Issues in the Pursuit of Molecular Medicine”. *Mol Med*, 15: 60-63, 2009. / Impact Factor: 5.908
- 22) M.V. Karamouzis, P.A. Konstantinopoulos, A.G. Papavassiliou: “Targeting c-Met as a strategy to overcome cross-talk related resistance to EGFR protein -targeting agents in cancer therapeutics”, *Lancet Oncol*, 10: 709-77, 2009. / Impact Factor: 17.764
- 23) A. Kotsinas, I.S. Pateras, P.S. Galanos, M.V. Karamouzis, P.P. Sfikakis, V.G. Gorgoulis: “Why is p53-inducible gene 3 rarely affected in cancer?”, *Oncogene*, 2010. / Impact Factor: 7.414
- 24) A.G. Pallis, M.V. Karamouzis: “DNA repair pathways and their implication in cancer treatment”, *Cancer Metastasis Rev*, 2010. / Impact Factor: 7.14
- 25) A. Argiris, M.V. Karamouzis, “Empowering induction therapy for locally advanced head and neck cancer” *Ann Oncol*, 2010 / Impact Factor: 6.452
- 26) Argiris, M.V. Karamouzis, W.E. Gooding, B.F. Branstetter, S. Zhong, L.E. Raez, P. Savvides, M. Romkes: “Phase II trial of pemetrexed and bevacizumab in patients with recurrent or metastatic head and neck cancer”, *J Clin Oncol*, 2011. / Impact Factor: 18.97
- 27) A. Argiris, M.V. Karamouzis, W.E. Gooding, B.F. Branstetter, S. Zhong, L.E. Raez, P. Savvides, M. Romkes “Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer”, *Ann Oncol*, 2011 / Impact Factor: 6.452